Research perspectives: The future of the management of metastatic triple-negative breast cancers (notice n° 504564)
[ vue normale ]
| 000 -LEADER | |
|---|---|
| fixed length control field | 01386cam a2200181 4500500 |
| 005 - DATE AND TIME OF LATEST TRANSACTION | |
| control field | 20250121083954.0 |
| 041 ## - LANGUAGE CODE | |
| Language code of text/sound track or separate title | fre |
| 042 ## - AUTHENTICATION CODE | |
| Authentication code | dc |
| 100 10 - MAIN ENTRY--PERSONAL NAME | |
| Personal name | Frenel, Jean-Sébastien |
| Relator term | author |
| 245 00 - TITLE STATEMENT | |
| Title | Research perspectives: The future of the management of metastatic triple-negative breast cancers |
| 260 ## - PUBLICATION, DISTRIBUTION, ETC. | |
| Date of publication, distribution, etc. | 2022.<br/> |
| 500 ## - GENERAL NOTE | |
| General note | 70 |
| 520 ## - SUMMARY, ETC. | |
| Summary, etc. | Triple-negative breast cancer (TNBC) is a heterogeneous disease with a poor prognosis. Until recently, this disease was solely treated with chemotherapy. However, it has been the subject of much research and therapeutic progress. The success of immunotherapy and antibody-drug conjugates (ADC) has finally opened up new possibilities for both advanced and early stages of the disease. In this review, we discuss the ongoing efforts to improve the effectiveness of immunotherapy through new approaches. We also review the numerous ADC in development and their targets. Finally, we examine the potential role of targeted therapies, such as PI3K/AKT/mTOR inhibitors and hormone therapy approaches. |
| 700 10 - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Zenatri, Morgan |
| Relator term | author |
| 700 10 - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Bachelot, Thomas |
| Relator term | author |
| 786 0# - DATA SOURCE ENTRY | |
| Note | Innovations & Thérapeutiques en Oncologie | Volume 8 | Special Issue 2 | 2022-12-02 | p. 20-24 | 2431-3203 |
| 856 41 - ELECTRONIC LOCATION AND ACCESS | |
| Uniform Resource Identifier | <a href="https://shs.cairn.info/journal-innovations-therapeutiques-en-oncologie-2025-HS2-page-20?lang=en&redirect-ssocas=7080">https://shs.cairn.info/journal-innovations-therapeutiques-en-oncologie-2025-HS2-page-20?lang=en&redirect-ssocas=7080</a> |
Pas d'exemplaire disponible.
Réseaux sociaux